Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to tame dangerous autoimmune flares

NCT ID NCT06388941

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an investigational drug called iptacopan to standard treatment helps people with active ANCA-associated vasculitis. The goal is to achieve and maintain remission—a state with no disease activity—for longer periods while reducing the need for steroid medications. It involves 84 adults with newly diagnosed or relapsing forms of this serious autoimmune condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arizona Arthritis and Rheumatology Research PLLC

    Mesa, Arizona, 85202, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Northwell Health

    New York, New York, 10028, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1180AAX, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, B1900AWT, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Concord, New South Wales, 2139, Australia

  • Novartis Investigative Site

    Westmead, New South Wales, 2145, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, 5000, Australia

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Innsbruck, Tyrol, 6020, Austria

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, 3000, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Novartis Investigative Site

    London, Ontario, N6A 5W9, Canada

  • Novartis Investigative Site

    Fleurimont, Quebec, J1H 5N4, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H4J 1C5, Canada

  • Novartis Investigative Site

    Québec, Quebec, G1R 2J6, Canada

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450003, China

  • Novartis Investigative Site

    Beijing, 100034, China

  • Novartis Investigative Site

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    Aarhus N, 8200, Denmark

  • Novartis Investigative Site

    Herlev, DK-2730, Denmark

  • Novartis Investigative Site

    Angers, 49933, France

  • Novartis Investigative Site

    Brest, 29200, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    Marseille, 13005, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Toulouse, 31054, France

  • Novartis Investigative Site

    Kirchheim unter Teck, Baden-Wurttemberg, 73230, Germany

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Ludwigshafen, 67063, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Szeged, 6725, Hungary

  • Novartis Investigative Site

    Plasencia, Caceres, 10600, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Istanbul, Pendik, 34899, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    Cambridge, CB2 0QQ, United Kingdom

Conditions

Explore the condition pages connected to this study.

ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS